After the company reported third-quarter earnings that were better than industry watchers’ forecasts, shares in Nektar Therapeutics (NASDAQ: NKTR) are popping 13.1% higher today as of 2:45 p.m. EST.
Nektar Therapeutics’ third-quarter top- and bottom-line figures came in ahead of analysts’ forecasts. The company’s sales increased $152.9 million from $36.3 million in the third quarter of 2016, and its net income of $60.9 million, or $0.39 per share, marked a big improvement from its net loss of $43.2 million, or $0.32 in the same quarter of 2016.